

In the papers by Bohm et al¹ and Dulai et al,² the following grant support statement was omitted: "This study was supported by the UCSD Gastroenterology T32 training grant (DK 0070202)." The authors apologise for this omission.

REFERENCES

1. Bohm M, Xu R, Zhang Y, et al; the VICTORY Collaboration. Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease. *Aliment Pharmacol Ther.* 2020;52:669-681.
2. Dulai PS, Amiot A, Peyrin-Biroulet L, et al; on Behalf of the GETAID OBSERV-IBD, VICTORY Cohorts Collaboration. A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease. *Aliment Pharmacol Ther.* 2020;51:553-564.